Previous 10 | Next 10 |
CAMBRIDGE, Mass., April 29, 2021 (GLOBE NEWSWIRE) -- Fulcrum Therapeutics, Inc. (Nasdaq: FULC), a clinical-stage biopharmaceutical company focused on improving the lives of patients with genetically defined rare diseases, today announced that its first quarter 2021 financial re...
CAMBRIDGE, Mass., April 09, 2021 (GLOBE NEWSWIRE) -- Fulcrum Therapeutics, Inc. (Nasdaq: FULC), a clinical-stage biopharmaceutical company focused on improving the lives of patients with genetically defined rare diseases, today presented the medicinal chemistry strategy for FTX...
CAMBRIDGE, Mass., March 24, 2021 (GLOBE NEWSWIRE) -- Fulcrum Therapeutics, Inc. (Nasdaq: FULC), a clinical-stage biopharmaceutical company focused on improving the lives of patients with genetically defined rare diseases, today announced that Judith A. Dunn, Ph.D. has been appoi...
– Demonstrated Whole-Body MRI captures heterogeneity and provides key disease severity and progression information correlated with FSHD clinical endpoints – – Demonstrated potential of FSHD-TUG and Emerald in-home assessments as accurate, low-burden...
Today, we dive into Fulcrum Therapeutics, a small biotech concern that just came public less than two years ago. Fulcrum Therapeutics recently did a capital raise and discontinued its COVID-19 efforts. It has two earlier stage efforts in development. A full analysis follows in the...
Fulcrum Therapeutics, Inc. (FULC) Q4 2020 Results Earnings Conference Call March 04, 2021, 08:00 AM ET Company Participants Christi Waarich - Director, Investor Relations and Corporate Communications Robert Gould - President & CEO Bryan Stuart - Chief Operating Officer Chris Moxham - Chie...
Fulcrum Therapeutics ([[FULC]] -8.1%) is trading lower today after the company announced the appointment of Bryan E. Stuart as its new president and chief executive officer following the retirement of the incumbent Robert J. Gould with effect from March 31.Upon his exit, Mr. Gould w...
Fulcrum Therapeutics (FULC): Q4 GAAP EPS of -$0.64 beats by $0.08.Revenue of $4.23M beats by $2.6M.Press Release For further details see: Fulcrum Therapeutics EPS beats by $0.08, beats on revenue
– Company on track to present data from Phase 2b ReDUX4 trial with losmapimod in facioscapulohumeral muscular dystrophy (FSHD) in late-2Q 2021 – – On track to report results from Phase 1 trial in healthy adult volunteers with FTX-6058 for sickle cell ...
– Robert J. Gould, Ph.D. announces retirement; will continue to serve as board member and advisor – – Bryan E. Stuart promoted to president and chief executive officer effective March 31, 2021 – CAMBRIDGE, Mass., March 04, 2...
News, Short Squeeze, Breakout and More Instantly...
Fulcrum Therapeutics Inc. Company Name:
FULC Stock Symbol:
NYSE Market:
Fulcrum Therapeutics Inc. Website:
CAMBRIDGE, Mass., July 24, 2024 (GLOBE NEWSWIRE) -- Fulcrum Therapeutics, Inc. ® (the “Company”) (Nasdaq: FULC), a clinical-stage biopharmaceutical company focused on developing small molecules to improve the lives of patients with genetically defined rare diseases, today a...
CAMBRIDGE, Mass., June 12, 2024 (GLOBE NEWSWIRE) -- Fulcrum Therapeutics, Inc. ® (the “Company”) (Nasdaq: FULC), a clinical-stage biopharmaceutical company focused on developing small molecules to improve the lives of patients with genetically defined rare diseases, today a...
CAMBRIDGE, Mass., June 06, 2024 (GLOBE NEWSWIRE) -- Fulcrum Therapeutics, Inc. ® (the “Company”) (Nasdaq: FULC), a clinical-stage biopharmaceutical company focused on developing small molecules to improve the lives of patients with genetically defined rare diseases, today a...